Isis Reacquires Cancer Compound From Lilly To Develop In-House
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly holds option to reacquire LY2275796 at the start of Phase III.
You may also be interested in...
Isis' Balancing Act: Diversify With Cancer, But Avoid High-Stakes Gambles
Isis tried a delicate balancing act during its May 20 pipeline update: it sought to accentuate its progress in branching out into cancer drug development, while also reassuring investors that its oncology spend is relatively modest and doesn't introduce major risk
Isis' Balancing Act: Diversify With Cancer, But Avoid High-Stakes Gambles
Isis tried a delicate balancing act during its May 20 pipeline update: it sought to accentuate its progress in branching out into cancer drug development, while also reassuring investors that its oncology spend is relatively modest and doesn't introduce major risk
Lilly Snatches ImClone Away From Bristol
Lilly’s $6.5 billion acquisition of ImClone will create an oncology “powerhouse” with 18 cancer drugs in clinical development.